Seer 2025 Q1 Earnings Revenue Grows 37% Despite Net Losses
Wednesday, May 14, 2025 5:18 am ET
Seer (SEER) reported its fiscal 2025 Q1 earnings on May 13th, 2025. Seer exceeded revenue expectations with a 37.1% increase to $4.21 million, surpassing the prior year's $3.07 million. However, the company reported a net loss of $19.95 million, slightly narrowing from last year's $20.68 million loss. The company maintained its full-year revenue guidance, indicating a stable outlook. Overall, the earnings performance suggests Seer is on a path to revenue recovery, despite ongoing losses.
Revenue
Seer's total revenue for Q1 2025 rose by 37.1% to reach $4.21 million, up from $3.07 million in Q1 2024. The product segment contributed $2.89 million, while service revenue amounted to $1.20 million. Revenue from related parties was $52,000, with other revenue contributing $60,000, rounding up the total to $4.21 million.
Earnings/Net Income
Seer's Q1 2025 loss per share widened to $0.34 from $0.32 in the previous year, marking a 6.3% increase. Despite this, the net loss narrowed slightly to $19.95 million from $20.68 million last year. The EPS indicates ongoing financial challenges.
Price Action
The stock price of Seer edged up by 1.05% over the latest trading day and increased by 1.59% over the past week, despite a 7.25% decline month-to-date.
Post Earnings Price Action Review
The strategy of buying SEER when revenues miss and holding for 30 days has shown potential in backtesting. This contrarian approach involves purchasing SEER ETF shares following a revenue miss, capitalizing on the possibility of a short-term price recovery. The rationale is that the market may have already reacted negatively to the revenue miss, thus creating a buying opportunity. Holding the shares for 30 days allows for potential short-term gains or a period of price consolidation. Data collection and strategy implementation involve gathering historical data and applying this strategy to SEER's component stocks. Performance is evaluated using metrics such as profit and loss, drawdown, and the Sharpe ratio. While this strategy aims to capture short-term price movements post-revenue miss, it may not perform consistently across all market conditions, particularly in extended bear markets. Backtesting can provide insights into the strategy's effectiveness, taking into consideration market environment, SEER's volatility, and frequency of revenue misses during the testing period.
CEO Commentary
Omid Farokhzad, Chief Executive Officer and Chair of the Board, expressed confidence in Seer's technology, stating, "our long-term vision and opportunity remain unchanged." He noted a strong start to the year with $4.2 million in revenue, highlighting increased demand for the Proteograph product suite. Farokhzad addressed macroeconomic challenges, including tariffs and government funding uncertainties, yet reaffirmed a disciplined investment strategy in R&D and share repurchases, emphasizing the company's strong balance sheet of approximately $285 million. His tone remained optimistic, as he stated, "we're still at the very beginning of this journey," indicating a commitment to expand access and drive growth in proteomics.
Guidance
Seer maintains its full-year revenue guidance at $17 million to $18 million for 2025, reflecting a 24% year-over-year growth at the midpoint. The guidance considers ongoing budget pressures and uncertainties in government funding, with approximately 30% of revenue coming from academic and government sectors. Farokhzad remarked on the potential impacts of tariffs on revenue, particularly regarding international customers, while noting that they do not expect significant effects on STAC services. Overall, the company anticipates a stable revenue performance amidst a cautious outlook.
Additional News
Seer has made strategic moves in recent weeks to strengthen its market position. The company expanded its partnership with Thermo Fisher Scientific, a significant development considering the proteomics market dynamics. This collaboration is expected to enhance workflow integration between Seer's sample preparation technology and Thermo's downstream analysis platforms. Additionally, Seer has been actively involved in share repurchase activities, reducing outstanding shares by around 10% in 2024. This move signals management's confidence in the company's valuation. Lastly, Seer secured a notable contract with Discovery Life Sciences to conduct a 10,000-sample study, further showcasing the growing demand for its Proteograph Product Suite.
Revenue
Seer's total revenue for Q1 2025 rose by 37.1% to reach $4.21 million, up from $3.07 million in Q1 2024. The product segment contributed $2.89 million, while service revenue amounted to $1.20 million. Revenue from related parties was $52,000, with other revenue contributing $60,000, rounding up the total to $4.21 million.
Earnings/Net Income
Seer's Q1 2025 loss per share widened to $0.34 from $0.32 in the previous year, marking a 6.3% increase. Despite this, the net loss narrowed slightly to $19.95 million from $20.68 million last year. The EPS indicates ongoing financial challenges.
Price Action
The stock price of Seer edged up by 1.05% over the latest trading day and increased by 1.59% over the past week, despite a 7.25% decline month-to-date.
Post Earnings Price Action Review
The strategy of buying SEER when revenues miss and holding for 30 days has shown potential in backtesting. This contrarian approach involves purchasing SEER ETF shares following a revenue miss, capitalizing on the possibility of a short-term price recovery. The rationale is that the market may have already reacted negatively to the revenue miss, thus creating a buying opportunity. Holding the shares for 30 days allows for potential short-term gains or a period of price consolidation. Data collection and strategy implementation involve gathering historical data and applying this strategy to SEER's component stocks. Performance is evaluated using metrics such as profit and loss, drawdown, and the Sharpe ratio. While this strategy aims to capture short-term price movements post-revenue miss, it may not perform consistently across all market conditions, particularly in extended bear markets. Backtesting can provide insights into the strategy's effectiveness, taking into consideration market environment, SEER's volatility, and frequency of revenue misses during the testing period.
CEO Commentary
Omid Farokhzad, Chief Executive Officer and Chair of the Board, expressed confidence in Seer's technology, stating, "our long-term vision and opportunity remain unchanged." He noted a strong start to the year with $4.2 million in revenue, highlighting increased demand for the Proteograph product suite. Farokhzad addressed macroeconomic challenges, including tariffs and government funding uncertainties, yet reaffirmed a disciplined investment strategy in R&D and share repurchases, emphasizing the company's strong balance sheet of approximately $285 million. His tone remained optimistic, as he stated, "we're still at the very beginning of this journey," indicating a commitment to expand access and drive growth in proteomics.
Guidance
Seer maintains its full-year revenue guidance at $17 million to $18 million for 2025, reflecting a 24% year-over-year growth at the midpoint. The guidance considers ongoing budget pressures and uncertainties in government funding, with approximately 30% of revenue coming from academic and government sectors. Farokhzad remarked on the potential impacts of tariffs on revenue, particularly regarding international customers, while noting that they do not expect significant effects on STAC services. Overall, the company anticipates a stable revenue performance amidst a cautious outlook.
Additional News
Seer has made strategic moves in recent weeks to strengthen its market position. The company expanded its partnership with Thermo Fisher Scientific, a significant development considering the proteomics market dynamics. This collaboration is expected to enhance workflow integration between Seer's sample preparation technology and Thermo's downstream analysis platforms. Additionally, Seer has been actively involved in share repurchase activities, reducing outstanding shares by around 10% in 2024. This move signals management's confidence in the company's valuation. Lastly, Seer secured a notable contract with Discovery Life Sciences to conduct a 10,000-sample study, further showcasing the growing demand for its Proteograph Product Suite.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.